Daiichi and AstraZeneca claim another breast cancer success, and further evidence of the ADC’s activity in very low HER2 expression.

A pipeline cull sees the US pharma joining AbbVie's exit, in the wake of Novartis’s big bet. 

Abstract titles reveal some of ASCO’s key datasets.

Belvarafenib heads back to Hanmi and LY6G6D targeting takes a blow.

The FDA's tough stance notwithstanding, Ojemda gets an accelerated green light.

The Swiss company is still interested in this antigen, after discontinuing two earlier clinical projects.